Project Grant R01DK143970
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Michigan $129,306 on December 9, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to define a novel neurocircuit for stress-induced hyperglycemia. The research investigates the neurobiological mechanisms underlying stress-induced hyperglycemia (SIH)—the rapid elevation of blood glucose in response to psychological or physical trauma....
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Miami $537,250 on June 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the neuronal entero-pancreatic circuit's role in glucose metabolism and insulin secretion. The recipient will uncover mechanisms coupling gut sensing to entero-pancreatic neurons, elucidate neurotransmitter pathways transmitting signals from the gut lumen to...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Michigan $785,969 on February 6, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate secretory pathway protein degradation mechanisms that maintain insulin biogenesis and secretion in pancreatic beta cells. The award funds research into how pancreatic beta cells maintain approximately one billion insulin molecules per cell...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health under the Department of Health and Human Services, awarded $717,030 to the University of Virginia on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to uncover neural circuits controlling body weight and metabolism. The research develops and applies RAMPANT (rabies afferent mapping by poly-A nuclear transcriptomics), a novel...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the Department of Health and Human Services National Institutes of Health, awarded the Regents of the University of Michigan $1,519,835 on September 24, 2025, to test a novel weight navigation program designed to overcome multilevel barriers to obesity treatment in primary care settings. The project grant (R01DK139094) supports research under the Diabetes, Digestive, and Kidney Diseases Extramural...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Midwestern University $710,812 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of intrinsic primary afferent neurons in intestinal nutrient sensing and obesity. The research uses molecular, behavioral, and electrophysiological approaches to uncover how intestinal sensory neurons modulate glucose absorption, lipid transport, and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Michigan $616,132 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop nanocarrier-based immunotherapeutic strategies for type-1 diabetes treatment. The research targets immune tolerance induction against type-1 diabetes through biomaterial nanocarriers designed for lymph node targeting, a key site for immune...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the Department of Health and Human Services National Institutes of Health, awarded $645,154 to the Regents of the University of Michigan on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research investigating the role of androgens in sex-specific metabolic inflammation (meta-inflammation) responses associated with obesity....
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Michigan $230,388 on December 11, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on sex-specific effects and the role of ovarian hormones in striatal-mediated food-seeking behavior. The research examines how excitatory neurotransmission, particularly glutamate signaling through calcium-permeable AMPA receptors in the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Trustees of Columbia University in the City of New York $838,425 on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate nutrient sensing mechanisms in pro-opiomelanocortin neurons. The research examines how lactate and glucose interact to regulate POMC neuronal activity and whole-body energy metabolism. The project focuses on the mechanism by which...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Michigan $672,600 on August 25, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the neural circuits that control glucose mobilization through the hypothalamus. The project, R01DK143970, will identify distinct populations of dorsomedial ventromedial nucleus neurons and determine how specific neural subtypes coordinate glucose production across different physiological contexts. The research addresses dysregulated glucose production in type 2 diabetes and stress hyperglycemia by examining three classes of hypothalamic neurons defined by molecular markers (LEPR, GLIPR1, and VGLUT3). Preliminary findings suggest these neuron populations activate different glucose-mobilizing mechanisms—including pituitary-adrenal axis signaling and sympathetic nervous system outflow—tailored to specific environmental or psychological stressors. Understanding these distinct neural circuits is intended to inform development of targeted treatments that address underlying pathology rather than symptomatic blood glucose normalization. Work is performed at the University of Michigan in Ann Arbor, Michigan. The period of performance runs through June 30, 2031. This is a Project Grant, the standard NIH research grant mechanism for investigator-initiated basic and clinical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $672.6k | 8/24/26 |